Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
08.04. | HHS cuts contract spend by 35%, with 334 pacts already terminated | ||
08.04. | Third Rock-backed Merida launches with $121M series A to fund autoimmune pipeline | ||
08.04. | J&J links FcRn blocker to sustained benefits as FDA ruling on potential blockbuster nears | ||
08.04. | Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint | ||
08.04. | KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal | ||
08.04. | Congressional commission urges action to maintain US biotech advantage over China | ||
07.04. | 'A slow-moving catastrophe': FDA cuts are like firing all hospital staff except doctors, Janet Woodcock says | ||
07.04. | Nordic Capital steps away from potential PureTech Health buyout | ||
07.04. | Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy | ||
07.04. | Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO | ||
07.04. | UK's Epsilogen acquires fellow immunoglobin biotech TigaTx to boost cancer antibody options | ||
07.04. | GSK pens $2.5B pact for ABL Bio's tech to help antibodies bypass blood-brain barrier | ||
04.04. | Trump administration faces mounting litigation as 16 states sue over NIH grant cuts | ||
04.04. | Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers | ||
04.04. | F-star charts new path, splitting from invoX after 2023's $161M acquisition | ||
04.04. | Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages | ||
04.04. | Apollomics tags out of TYG oncology pact to cut costs, extend runway into 2026 | ||
03.04. | Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3 | ||
03.04. | Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks | ||
03.04. | Aldeyra's dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery | ||
03.04. | BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs | ||
03.04. | Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics | ||
02.04. | Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts | ||
02.04. | Elon Musk expected to step down from DOGE leadership role: Politico | ||
02.04. | 'Patently illegal': NIH and HHS face new lawsuit over $1.1B in revoked research grants |